News

The Manila Times23h
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) ...
The Lancet3h
Efficacy of digital health technologies in the management of inflammatory bowel disease: an umbrella review
The use of digital health technology (DHT) is increasing worldwide. Clinical trials assessing available health tools for the ...
Checkpoint Therapeutics, Inc: Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
UNLOXCYT (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merge ...
Gastroenterology Advisor6h
Biotherapeutic Rebyota Prevents Recurrent CDI in Immunocompromised Patients
Data from a phase 3 study indicated the microbiota-based live biotherapeutic RBL was safe and efficacious for recurrent CDI prevention in immunocompromised patients.